Structural 12/15

Medstream360 members only

To view this video and learn more about the procedure please Login or Register.
Membership is free!

The Mount Sinai Hospital

1468 Madison Avenue, New York,
New York 10029

CoreValve Evolut-R TAVR (29mm) via Percutaneous Femoral Access

Core valve TAVR

An 84 year-old male presented with progressive shortness of breath and chest discomfort – NYHA class II, with a history of hypertension, I vessel CAD, COPD, TIA, s/p BAV on 10/2/15, s/p rt. radical nephrectomy, stage III CKD, and h/o CA prostrate. TTE revealed severe AS, peak/mean aortic gradient = 85/56 mmHg, AVA = 0.8 sq cm, aortic peak velocity = 4.6 m/sec and LVEF 77%. CT angio showed minimum diameters of 0.7 x 0.8 cm for right and 0.7 x 0.7 cm for left common femoral arteries and aortic annulus of 2.6 X 2.2 cm (average 2.4 cm). The STS risk mortality is 9.5 % and the Logistic Euroscore mortality is 20.27 %. Patient was determined to be very high risk for surgical AVR due to advanced age, high right diaphragm, renal insufficiency, COPD, and obesity. Patient is now planned for CoreValve Evolut-R TAVR (29mm) via percutaneous femoral access under conscious sedation.


Case Presentation


Lorem ipsum dolor sit amet consectetur adipisicing elit. A, dignissimos?